Literature DB >> 24117005

TRAIL receptor deficiency sensitizes mice to dextran sodium sulphate-induced colitis and colitis-associated carcinogenesis.

Jieqing Zhu1, Longfei Chen, Juan Shi, Shilian Liu, Yanxin Liu, Dexian Zheng.   

Abstract

Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) and its receptor (TRAIL-R) play important roles in immune regulation and cancer cell death. Although TRAIL has been shown to induce chemokine release in various tumour cells, the function of TRAIL-R in the development of colitis and colitis-associated carcinogenesis has not been explored. In this study, we found that TRAIL-R-deficient mice exhibited a higher incidence of colitis and colitis-associated cancer than that of wild-type (WT) mice, and TRAIL-R expression was down-regulated in WT mice that were fed dextran sulphate sodium. Chemokines, including CCL2 and CXCL1, were highly expressed in the serum and inflammatory colon tissues of TRAIL-R(-/-) mice compared with WT mice, and TRAIL-R(-/-) mice showed a marked infiltration of immune cells during colitis. Hyperactivation of Janus kinase and nuclear factor-κB in colon epithelial cells was also observed, which correlated with the severity of colonic inflammation in TRAIL-R(-/-) mice. These data suggest that TRAIL-R plays a protective role in chemical-induced colon injury and negatively regulates mucosal immune responses.
© 2013 John Wiley & Sons Ltd.

Entities:  

Keywords:  colitis; colitis-associated cancer; inflammation; tumour necrosis factor-related apoptosis-inducing ligand receptor

Mesh:

Substances:

Year:  2014        PMID: 24117005      PMCID: PMC3904242          DOI: 10.1111/imm.12181

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  39 in total

1.  TRAIL-R as a negative regulator of innate immune cell responses.

Authors:  Gretchen E Diehl; Herman H Yue; Kristina Hsieh; Anna A Kuang; Mary Ho; Lisa A Morici; Laurel L Lenz; Dragana Cado; Lee W Riley; Astar Winoto
Journal:  Immunity       Date:  2004-12       Impact factor: 31.745

2.  Loss of TRAIL-R does not affect thymic or intestinal tumor development in p53 and adenomatous polyposis coli mutant mice.

Authors:  H H Yue; G E Diehl; A Winoto
Journal:  Cell Death Differ       Date:  2005-01       Impact factor: 15.828

Review 3.  NLRs join TLRs as innate sensors of pathogens.

Authors:  Fabio Martinon; Jürg Tschopp
Journal:  Trends Immunol       Date:  2005-08       Impact factor: 16.687

4.  Implication of TNF-related apoptosis-inducing ligand in inflammatory intestinal epithelial lesions.

Authors:  Bernadette Begue; Harald Wajant; Jean-Christophe Bambou; Laurent Dubuquoy; Daniela Siegmund; Jean-François Beaulieu; Danielle Canioni; Dominique Berrebi; Nicole Brousse; Pierre Desreumaux; Jacques Schmitz; Michael J Lentze; Oliver Goulet; Nadine Cerf-Bensussan; Frank M Ruemmele
Journal:  Gastroenterology       Date:  2006-06       Impact factor: 22.682

5.  DR5 knockout mice are compromised in radiation-induced apoptosis.

Authors:  Niklas Finnberg; Joshua J Gruber; Peiwen Fei; Dorothea Rudolph; Anka Bric; Seok-Hyun Kim; Timothy F Burns; Hope Ajuha; Robert Page; Gen Sheng Wu; Youhai Chen; W Gillies McKenna; Eric Bernhard; Scott Lowe; Tak Mak; Wafik S El-Deiry
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

6.  TNF-related apoptosis-inducing ligand (TRAIL)/Apo2L suppresses experimental autoimmune encephalomyelitis in mice.

Authors:  Erika Cretney; Jonathan L McQualter; Nobuhiko Kayagaki; Hideo Yagita; Claude C A Bernard; Iqbal S Grewal; Avi Ashkenazi; Mark J Smyth
Journal:  Immunol Cell Biol       Date:  2005-10       Impact factor: 5.126

7.  Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor.

Authors:  G S Wu; T F Burns; Y Zhan; E S Alnemri; W S El-Deiry
Journal:  Cancer Res       Date:  1999-06-15       Impact factor: 12.701

8.  Chemically induced mouse models of intestinal inflammation.

Authors:  Stefan Wirtz; Clemens Neufert; Benno Weigmann; Markus F Neurath
Journal:  Nat Protoc       Date:  2007       Impact factor: 13.491

9.  Cutting edge: TRAIL deficiency accelerates hematological malignancies.

Authors:  Nadeen Zerafa; Jennifer A Westwood; Erika Cretney; Sally Mitchell; Paul Waring; Manuela Iezzi; Mark J Smyth
Journal:  J Immunol       Date:  2005-11-01       Impact factor: 5.422

Review 10.  Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation.

Authors:  Steven H Itzkowitz; Xianyang Yio
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2004-07       Impact factor: 4.052

View more
  6 in total

1.  Anti-mouse CD52 monoclonal antibody ameliorates intestinal epithelial barrier function in interleukin-10 knockout mice with spontaneous chronic colitis.

Authors:  Honggang Wang; Jianning Dong; Peiliang Shi; Jianhui Liu; Lugen Zuo; Yi Li; Jianfeng Gong; Lili Gu; Jie Zhao; Liang Zhang; Wei Zhang; Weiming Zhu; Ning Li; Jieshou Li
Journal:  Immunology       Date:  2015-02       Impact factor: 7.397

2.  TRAIL-Mediated Suppression of T Cell Receptor Signaling Inhibits T Cell Activation and Inflammation in Experimental Autoimmune Encephalomyelitis.

Authors:  I-Tsu Chyuan; Hwei-Fang Tsai; Chien-Sheng Wu; Chi-Chang Sung; Ping-Ning Hsu
Journal:  Front Immunol       Date:  2018-01-22       Impact factor: 7.561

3.  Cancer preventive effect of recombinant TRAIL by ablation of oncogenic inflammation in colitis-associated cancer rather than anticancer effect.

Authors:  Joo-Young Kim; Young-Mi Kim; Jong-Min Park; Young Min Han; Kang Choon Lee; Ki Baik Hahm; Suntaek Hong
Journal:  Oncotarget       Date:  2017-12-07

4.  Suppressed humoral immunity is associated with dengue nonstructural protein NS1-elicited anti-death receptor antibody fractions in mice.

Authors:  Chung-Lin Tsai; Der-Shan Sun; Mei-Tzu Su; Te-Sheng Lien; Yen-Hsu Chen; Chun-Yu Lin; Chung-Hao Huang; Chwan-Chuen King; Chen-Ru Li; Tai-Hung Chen; Yu-Hsiang Chiu; Chun-Chi Lu; Hsin-Hou Chang
Journal:  Sci Rep       Date:  2020-04-14       Impact factor: 4.379

5.  Inflammatory bowel disease-associated ubiquitin ligase RNF183 promotes lysosomal degradation of DR5 and TRAIL-induced caspase activation.

Authors:  Yan Wu; Yuka Kimura; Takumi Okamoto; Koji Matsuhisa; Rie Asada; Atsushi Saito; Fumika Sakaue; Kazunori Imaizumi; Masayuki Kaneko
Journal:  Sci Rep       Date:  2019-12-30       Impact factor: 4.379

Review 6.  New Perspectives in the Study of Intestinal Inflammation: Focus on the Resolution of Inflammation.

Authors:  Miguel Camba-Gómez; Oreste Gualillo; Javier Conde-Aranda
Journal:  Int J Mol Sci       Date:  2021-03-05       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.